- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02847351
A Mild Supplementation of Arabinoxylan Fiber Improves Homa Index in Overweight and Obese Subjects.
A Mild Supplementation of Arabinoxylan Fiber Improves Homa Index in Overweight and Obese Subjects. Results From a Randomized Cross Over Trial.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Pavia, Italy, 27100
- irccs policlinico san matteo foundation
-
-
PV
-
Pavia, PV, Italy, 27100
- Internal Medicine Department, Clinica Medica II, IRCCS San Matteo Foundation
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- males and females
- age ≥ 18 years
- Body mass Index ≥ 27
Exclusion Criteria:
- diabetes mellitus
- already established organ damage
- debilitating diseases
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Placebo Comparator: Control Diet (CD)
Period 1(the first 4 weeks): 10 subjects were randomly assigned to Control Diet: they replaced for 4 weeks all the carbohydrates consumed in day (bread, pasta, runks) with crackers produced with a normal white grain flour.
After this period they crossed to period 2 (the second 4 weeks of treatment) without any wash out: they replaced for 4 weeks all the carbohydrates consumed in day (bread, pasta, runks) with crackers produced with Arabinoxylan-enriched flour.
|
19 free-living subjects (16 F/ 3M) attending from one year the Outpatient Obesity Clinic Policlinico S. Matteo were enrolled. All subjects were already reached weight loss and were in a sort of "weight steady state". Based on 7-day food diary, a nutritionist composed 19 isocaloric diets, replacing all consumed carbohydrates with normal or AX crackers. The mean carbohydrates intake was 189.5g, with total fiber 20.6g. In AX diet total fiber was 25.3g/day (20.6 plus 4.68g of AX). Height, weight, waist circumference were obtained at time 0, at week 4 and 8. At every time were collected blood samples for glucose, insulin, total cholesterol, HDL-chol., tryglicerides, plasma acyl and des-acyl ghrelin. Glucose and insulin were , also collected 2 h after a 75 g oral glucose tolerance test (OGTT).
Other Names:
|
|
Experimental: Arabinoxylan Diet (AXD)
Period 1(the first 4 weeks): 9 subjects were randomly assigned to Arabinoxylan-Diet: they replaced for 4 weeks all the carbohydrates consumed in day with crackers baked with an Arabinoxylan-enriched flour.
After this period they crossed to period 2 (the second 4 weeks of treatment) without any wash out: they replaced for 4 weeks all the carbohydrates consumed in day with crackers produced with a normal white grain flour
|
19 free-living subjects (16 F/ 3M) attending from one year the Outpatient Obesity Clinic Policlinico S. Matteo were enrolled. All subjects were already reached weight loss and were in a sort of "weight steady state". Based on 7-day food diary, a nutritionist composed 19 isocaloric diets, replacing all consumed carbohydrates with normal or AX crackers. The mean carbohydrates intake was 189.5g, with total fiber 20.6g. In AX diet total fiber was 25.3g/day (20.6 plus 4.68g of AX). Height, weight, waist circumference were obtained at time 0, at week 4 and 8. At every time were collected blood samples for glucose, insulin, total cholesterol, HDL-chol., tryglicerides, plasma acyl and des-acyl ghrelin. Glucose and insulin were , also collected 2 h after a 75 g oral glucose tolerance test (OGTT).
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Reduction of Homa Index after Ax Diet vs CD Diet
Time Frame: 4 weeks of arabinoxylan dietetic supplementation
|
The study aimed to investigate whether an Arabinoxylan enriched crackers consumption for 4 weeks in overweight or obese patients without diabetes mellitus have specific healthy effects on glycemic control, evaluated as reduction of Homa Index.
|
4 weeks of arabinoxylan dietetic supplementation
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Improvement of lipidic profile after AxDiet vs CD Diet
Time Frame: 4 weeks of arabinoxylan dietetic supplementation
|
The study aimed to investigate whether an Arabinoxylan enriched crackers consumption for 4 weeks had some benefic effects on lipids.
|
4 weeks of arabinoxylan dietetic supplementation
|
|
Improvement of weight after AxDiet vs CD Diet
Time Frame: 4 weeks of arabinoxylan dietetic supplementation
|
We investigate whether an Arabinoxylan enriched crackers consumption for 4 weeks had some effects on weight loss in obese or overweight subjects.
|
4 weeks of arabinoxylan dietetic supplementation
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Chiara Muggia, Medicine, irccs policlinico san matteo foundation
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 30200/9334
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Nutritional and Metabolic Diseases
-
Centro de Investigación en Alimentación y Desarrollo...Universidad de SonoraCompletedNutritional and Metabolic Disease
-
Chong Kun Dang PharmaceuticalCompletedEndocrine, Nutritional and Metabolic DiseasesKorea, Republic of
-
Chong Kun Dang PharmaceuticalCompletedEndocrine, Nutritional and Metabolic DiseasesKorea, Republic of
-
Chong Kun Dang PharmaceuticalCompletedEndocrine, Nutritional and Metabolic DiseasesKorea, Republic of
-
PharmanexUtah State University; Texas Diabetes & Endocrinology, P.A.CompletedOther Endocrine/Nutritional/Metabolic DisorderUnited States
-
Hadassah Medical OrganizationRecruitingSedentary Behavior | Nutritional and Metabolic DiseaseIsrael
-
Physicians Committee for Responsible MedicineCompletedDietary Modification | Nutritional and Metabolic DiseaseUnited States
-
Isfahan University of Medical SciencesCompletedNutritional and Metabolic DiseaseIran, Islamic Republic of
-
University of GuadalajaraCompletedNutritional and Metabolic DiseaseMexico
-
Isfahan University of Medical SciencesUnknownNutritional and Metabolic DiseaseIran, Islamic Republic of
Clinical Trials on Arabinoxylan Diet
-
Comet Bio Inc.Biofortis, Merieux NutriSciencesUnknownGastrointestinal Tolerance
-
University of CopenhagenCompletedWeight Loss | Overweight and ObesityDenmark
-
Fugeia NVCompleted
-
KU LeuvenCompleted
-
Purdue UniversityRural Development Administration (RDA) of the Republic of KoreaNot yet recruiting
-
University of MiamiDaiwa Health DevelopmentCompletedHuman Immunodeficiency Virus InfectionUnited States
-
University of Southern CaliforniaCompletedInflammation in HIV InfectionUnited States
-
University of ReadingUnknownOverweight and ObesityUnited Kingdom
-
University of AberdeenKarolinska Institutet; Universidad de Murcia; University of Leeds; University of... and other collaboratorsCompletedOverweight and ObesityUnited Kingdom
-
Aarhus University HospitalUniversity of AarhusCompleted